SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)
$IRMD
Medical/Dental Instruments
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/12/2023 | $50.00 | Buy | Lake Street |
Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 millionReports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 millionIradimed is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025, at 5:15 p.m. PT WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD), a leader in developing innovative Magnetic Resonance Imaging compatible medical devices, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2024. Iradimed anticipates total reve
WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), a leading provider of innovative magnetic resonance imaging ("MRI") compatible medical devices and the only provider of a non-magnetic intravenous ("IV") infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The Company presentation will take place on Wednesday, January 15, 2025, at 5:15 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Events and Presentations" section of the Company's investor web
WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. "We are honored to be included for the second consecutive year on Forbes' List of America's Most Successful Small-Cap Companies," said Roger Susi, President and Chief Executive Officer o
WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,
Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously
Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), today announced it has been ranked 24th on Forbes' list of America's Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. "We are honored to be included for the second consecutive year on Forbes' List of America's Most Successful Small-Cap Companies," said Roger Susi, President and Chief Executive Officer o
Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023.Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62. Declares a regular quarterly cash dividend of $0.15 per common share for the fourth quarter of 2024, payable on November 25, 2024. WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial result
WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIb21de778973841f8add41c2c49939c39. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be avail
8-K - IRADIMED CORP (0001325618) (Filer)
144 - IRADIMED CORP (0001325618) (Subject)
144 - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)